Home » Stocks » HEPA

Hepion Pharmaceuticals, Inc. (HEPA)

Stock Price: $1.56 USD -0.01 (-0.64%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $1.57 +0.01 (0.64%) May 13, 6:33 PM
Market Cap 117.01M
Revenue (ttm) n/a
Net Income (ttm) -20.36M
Shares Out 9.68M
EPS (ttm) -10.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $1.56
Previous Close $1.57
Change ($) -0.01
Change (%) -0.64%
Day's Open 1.58
Day's Range 1.45 - 1.59
Day's Volume 2,971,835
52-Week Range 1.45 - 4.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of...

1 week ago - GlobeNewsWire

EDISON, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven thera...

2 weeks ago - GlobeNewsWire

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

Other stocks mentioned: AGRX, AQMS, CATB, CKPT, IFRX, LLNW
1 month ago - InvestorPlace

EDISON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven thera...

1 month ago - GlobeNewsWire

Hepion to include ENDRA's TAEUS Ⓡ technology in Phase 2b trial of CRV431 ANN ARBOR, MI and EDISON, NJ / ACCESSWIRE / March 18, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic...

Other stocks mentioned: NDRA
1 month ago - Accesswire

EDISON, NJ / ACCESSWIRE / March 11, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic d...

2 months ago - Accesswire

EDISON, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment o...

2 months ago - GlobeNewsWire

EDISON, NJ / ACCESSWIRE / January 5, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic ...

4 months ago - Accesswire

CRV431 Demonstrated to be Generally Safe and Well Tolerated Clinically Significant Reductions in Important Biomarkers, ALT and AST, Observed in 28 Days Study Continuing with Higher Dose EDISON, NJ / ACC...

4 months ago - Accesswire

- DSMB Review After Completion of the First Dose Cohort Affirmed No Safety or Tolerability Concerns with CRV431 in NASH Patients - - DSMB Recommended the AMBITION Study Continue with Final Dosing Cohort...

4 months ago - Accesswire

- IND Expands Potential Indications for CRV431 Beyond NASH to Include COVID-19 - - CRV431 Poised to Move Directly into Phase 2 Clinical Study for COVID-19 - - Company May Seek Partnership(s) for COVID-1...

4 months ago - Accesswire

Hepion Pharmaceuticals (HEPA) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

Investors need to pay close attention to Hepion (HEPA) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical Trials

10 months ago - Seeking Alpha

Hepion Pharmaceuticals (NASDAQ: HEPA) shares are trading higher after the company reported its CRV431 demonstrated efficacy in Kidney Fibrosis.

10 months ago - Benzinga

The coronavirus pandemic has delivered a shock to our economy, and the severity will be dependent on whether the "curve is flattened".

Other stocks mentioned: AHPI, GILD, GNMK, NVS, REGN
1 year ago - Seeking Alpha

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: HSII, JBGS, NWBI, THG
1 year ago - Zacks Investment Research

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: KOF, NWBI, RUBI, THG
1 year ago - Zacks Investment Research

Hepion Pharmaceuticals And Neoleukin Therapeutics: 2 Micro-Cap Pharmaceutical Stocks Priced For 'Non Success' With Promising Drugs

1 year ago - Seeking Alpha

Hepion Pharmaceuticals And Neoleukin Therapeutics: Two Micro Cap Pharmaceutical Stocks Priced For "Non Success" With Promising Drugs

1 year ago - Seeking Alpha

Shares of Hepion Pharmaceuticals Inc (NASDAQ: HEPA), formerly ContraVir Pharma, are ripping higher after the thinly-traded, nano-cap biotech announced results from an animal study of its lead product ca...

1 year ago - Benzinga

Shares of Hepion Pharmaceuticals Inc. rocketed 57% in active trading to pace all premarket gainers, after the biopharmceutical company announced positive results from a preclinical study of its CRV431 l...

1 year ago - Market Watch

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

Other stocks mentioned: BBC, BBP, BTEC, SBIO
1 year ago - Zacks Investment Research

Shares of Hepion Pharmaceuticals Inc. HEPA, -4.94% soared 45% in very active premarket trading Thursday, after the biopharmaceutical company published data showing potential for its CRV431 to be a drug ...

1 year ago - Market Watch

About HEPA

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered... [Read more...]

Industry
Biotechnology
CEO
Robert Foster
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
HEPA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for HEPA stock is "Buy." The 12-month stock price forecast is 6.33, which is an increase of 305.77% from the latest price.

Price Target
$6.33
(305.77% upside)
Analyst Consensus: Buy